RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 74 filers reported holding RUBIUS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,129,936 | -63.5% | 12,376,153 | -8.0% | 0.00% | -100.0% |
| Q3 2022 | $5,838,000 | -49.3% | 13,457,499 | -0.5% | 0.00% | 0.0% |
| Q2 2022 | $11,509,000 | -84.6% | 13,528,925 | +0.0% | 0.00% | -83.3% |
| Q1 2022 | $74,539,000 | -42.9% | 13,527,993 | +0.4% | 0.01% | -40.0% |
| Q4 2021 | $130,485,000 | -46.1% | 13,479,866 | -0.4% | 0.01% | -47.4% |
| Q3 2021 | $241,871,000 | -26.8% | 13,527,493 | 0.0% | 0.02% | -26.9% |
| Q2 2021 | $330,206,000 | -7.9% | 13,527,493 | 0.0% | 0.03% | -16.1% |
| Q1 2021 | $358,479,000 | +315.1% | 13,527,493 | +18.9% | 0.03% | +287.5% |
| Q4 2020 | $86,361,000 | +68.5% | 11,378,267 | +11.3% | 0.01% | +60.0% |
| Q3 2020 | $51,240,000 | -17.9% | 10,227,525 | -2.1% | 0.01% | -28.6% |
| Q2 2020 | $62,443,000 | +40.6% | 10,441,895 | +4.6% | 0.01% | +16.7% |
| Q1 2020 | $44,421,000 | -49.0% | 9,982,171 | +8.9% | 0.01% | -40.0% |
| Q4 2019 | $87,090,000 | +41.9% | 9,167,292 | +17.3% | 0.01% | +42.9% |
| Q3 2019 | $61,368,000 | -48.5% | 7,817,630 | +3.2% | 0.01% | -50.0% |
| Q2 2019 | $119,118,000 | -6.2% | 7,572,660 | +7.9% | 0.01% | -6.7% |
| Q1 2019 | $127,057,000 | +26.1% | 7,019,730 | +8.9% | 0.02% | +7.1% |
| Q4 2018 | $100,792,000 | -28.5% | 6,446,068 | +3.5% | 0.01% | -12.5% |
| Q3 2018 | $140,907,000 | – | 6,226,764 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |